Tolerance and chronic rejection

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 356, Issue 1409, 2001, Pages 727-738

  Womer, K L ^a   Lee, R S ^a   Madsen, J C ^a   Sayegh, M H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alloantigen; Chronic allograft dysfunction; Chronic allograft nephropathy; Chronic rejection; Tolerance; Transplantation

Indexed keywords

EID: 0035967478     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2001.0852     Document Type: Review

References (141)

1. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
2. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants. Influence of Fas-mediated apoptosis
3. Risk factors for chronic rejection in renal allograft recipients
4. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection
5. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
6. Early versus late acute renal allograft rejection: Impact on chronic rejection
7. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens
8. A role for CD95 ligand in preventing graft rejection
9. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function
10. Tolerance to rat liver allografts. III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues
11. High-dose/activation-associated tolerance: A mechanism for allograft tolerance
12. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
13. Tolerance induction by intrathymic inoculation prevents chronic renal allograft rejection
14. Early rejection: Determining the fate of renal transplants
15. Kidney transplantation from living unrelated donors
16. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen
17. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury
18. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection
19. Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival
20. In vivo mechanisms of acquired rhymic tolerance
21. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
22. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2
23. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
24. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice
25. Pathology of chronic rejection
26. Immunosuppressive strategies in transplantation
27. Transplantation tolerance: The concept and its applicability
28. Balancing the immune system for tolerance: A case for regulatory CD4 cells
29. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: A means for graft rejection and immunosuppression
30. The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression
31. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
32. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
33. Living unrelated donor kidney transplantation
34. Fas ligand-induced apoptosis as a mechanism of immune privilege
35. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants
36. Risk factors for chronic rejection in pediatric renal allograft recipients
37. An alternative view of injury and chronic allograft dysfunction: The case for cellular senescence
38. Differential effects of the immunosuppressants cyclosporine A, FK 506, and KM 2210 on cytokine gene expression
39. Costimulatory function of CD40L, CD80 and CD86 in vascularized murine cardiac allograft rejection
40. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes
41. Improved graft survival after renal transplantation in the United States, 1988 to 1996
42. Comparison of chimeric acid and non-chimeric tolerance using posttransplant total lymphoid irradiation: Cytokine expression and chronic rejection
43. + T cell tolerance and linked suppression
44. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans
45. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection
46. The relationship between acute rejection and chronic rejection is highly dependent on specific MHC matching: A multi-strain rat heterotopic heart transplant study
47. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis
48. Cytomegalovirus nucleic acids in allografted hearts
49. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
50. Immunologic factors: The major risk for decreased long-term renal allograft survival
51. Features of acute rejection that increase risk for chronic rejection
52. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome
53. The in vivo mechanisms of action of CTLA4Ig
54. Variable oral absorption of cyclosporine A. A biopharmaceutical risk factor for chronic renal allograft rejection
55. Long-term outcome and allo-antibody production in a non-myeloablative regimen for induction of renal allograft tolerance
56. - T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4
57. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection
58. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
59. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo
60. Primate renal transplants using immunotoxin
61. Effect of pravastatin on outcomes after cardiac transplantation
62. Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4
63. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways
64. The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts
65. Acute cytomegalovirus infection induces a subendothelial inflammation (endotheliolitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis
66. Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft
67. Late graft dysfunction after prolonged cold ischemia of the donor kidney: Inhibition by cyclosporine
68. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4
69. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
70. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients
71. Immunosuppressive effects of hCTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
72. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
73. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses
74. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
75. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants
76. Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells
77. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection
78. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine
79. + T cells
80. Half-life and risk factors for kidney transplant outcome - Importance of death with function
81. The impact of an acute rejection episode on long-term renal allograft survival (t1/2)
82. Cyclosporine-associated chronic nephropathy
83. Sequential cytokine dynamics in chronic rejection of rat renal allografts: Key roles for RANTES and MCP-1
84. Manipulation of cytokine networks in transplantation: False hope or realistic opportunity for tolerance?
85. Acute vascular rejection of the coronary arteries in human heart transplantation: Pathology and correlations with immunosuppression and cytomegalovirus infection
86. Hyperlipidemia in renal transplant recipients: Natural history and response to treatment
87. Induction of infectious tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody treated sensitized rat recipients
88. Type 2 helper T cell-type cytokines and the development of 'infectious' tolerance in rat cardiac allograft recipients
89. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study
90. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction
91. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection
92. Are Th2 helper lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival
93. Acute rejection of rat renal allografts is accelerated by donor brain death
94. Time dependency of factors affecting renal allograft survival
95. Apoptosis within spontaneously accepted mouse liver allografts: Evidence for deletion of cytotoxic T cells and implications for tolerance induction
96. 'Infectious' transplantation tolerance
97. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat
98. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients
99. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
100. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity
101. Improved long-term graft outcome in lung transplant recipients who have donor antigen-specific hyporeactivity
102. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients
103. Induction of specific tolerance to class I-disparate renal allografts in miniature swine with cyclosporine
104. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis
105. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity
106. Role of indirect allo-recognition in allograft rejection
107. The role of T-cell costimulatory activation pathways in transplant rejection
108. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
109. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients
110. A cell culture model for T lymphocyte clonal anergy
111. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
112. Intrathymic tolerance in the Lewis to F344 chronic cardiac allograft rejection model
113. Induction of allograft nonresponsiveness after intrathymic inoculation with donor class I allopeptides. II. Evidence for persistent chronic rejection despite high levels of donor microchimerism
114. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
115. Cardiac allograft tolerance: Failure to develop in interleukin-4-deficient mice correlates with unusual allosensitization patterns
116. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome
117. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tarolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group
118. IL-2 knockout recipient mice reject islet cell allografts
119. Prospects and applicability of molecular diagnosis of allograft rejection
120. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4Ig and anti-CD40 ligand monoclonal antibody
121. Transplantation tolerance: Fooling mother nature
122. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat
123. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury
124. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney inhibition by a soluble P-selectin ligand
125. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation
126. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts
127. High survival rates of kidney transplants from spousal and living unrelated donors
128. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy
129. Both alloantigen-dependent and -independent factors influence chronic allograft rejection
130. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
131. Indirect allorecognition of MHC allopeptides in human renal transplant recipients with chronic graft dysfunction
132. The role of indirect allorecognition in experimental late acute rejection
133. Transplantation tolerance - Where do we stand?
134. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells
135. Mixed chimerism as an approach for the induction of transplantation tolerance
136. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
137. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
138. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
139. T-cell recognition of allograft target antigens
140. Chronic allograft dysfunction: Mechanisms and new approaches to therapy
141. The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model